⚡Adding Ribociclib to Hormone Therapy Improves Outcomes for Patients With Early Breast Cancer: Study
By ANI
A study found that patients with early hormone-receptor (HR) positive/HER2 negative breast cancer had a significant advantage in invasive disease-free survival when ribociclib, a targeted therapy medicine, was added to hormone treatment.